Review of plasma anti-aggregants and their indications in primary care. Eight years later...;Revisión de los antiagregantes plaquetarios y sus indicaciones en atención primaria. Ocho años después...

Atencion Primaria

Volumn 31, Issue 4, 2003, Pages 252-263

  Blasco Valle, Mariano ^a,c   Lucia Cuesta J F ^b  

^a CENTRO DE SALUD DELICIAS SUR   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; FLURBIPROFEN; ICOSAPENTAENOIC ACID; INDOBUFEN; PENTOXIFYLLINE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFINPYRAZONE; TICLOPIDINE; TRIFLUSAL;

BRAIN ISCHEMIA; DIARRHEA; DRUG INDICATION; HUMAN; INTERMITTENT CLAUDICATION; MORTALITY; NEUTROPENIA; PRIMARY MEDICAL CARE; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOEMBOLISM;

EID: 0345505317     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13044902     Document Type: Review

References (73)

1. Blasco M, Vitoria A, Esteban M. Antiagregantes plaquetarios: revisión de sus indicaciones en atención primaria. Aten Primaria 1993;11:142-50.
2. Crononwett JJF, McKay, Zalenock GB, Withehose WM, Rabioleet J. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Surgery 1986;100:369-82.
3. Scheffler P, De la Hamette D, Gross J. Intensive training in stage IIb of peripheral arterial occlusive disease: the additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994;90:818-22.
4. The ICAI Study Group. Prostanoids for chronic critical leg ischemia: a ramdomized, controlled, open-label trial with prostaglandin E1. Ann Inter Med 1999;130:412-21.
5. Belch JJF, Bell PRF, Creissen D. Ramdomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997;95: 2298-302.
6. Bousser MG, Eschwege E, Hagueman H, Leffau Connier JM, Benton L, Corners, et al. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of atherotrhombotic cerebral ischaemia. Stroke 1983; 14:5-14.
7. Drener HC, Cunha L, Forbes C, Kummer H, Carnig F, Rosselt W, et al. European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
8. Radack K, Wyderski RJ. Conservative management of intermitent claudication. Ann Int Med 1990;113:135-46.
9. Money SR, Herd JA, Isaacsohn JL. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27: 267-75.
10. Dawson DL, Cutler BS, Meissner MH, Hagino RT, Beeve HG, DeManobus CA, et al. Cilostazol has beneficial effects in the treatment of intermittent claudication: results from a multicenter, randomized, prospective, double blind trial. Circulation 1998;98:678-86.
11. Dawson DL, DeMaioribus CA, Hagino RT. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999;178: 141-6.
12. Beebe HG, Dawson DL, Cutler BS, DeMariobus CA, Hagino RT, Currier JA, et al. A new pharmacologic treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Inter Med 1999;159:2041-50.
13. Gent M, Easton J, Chachinsky V, Hammel J, Rosedo V, Rossel N, et al. CATS Canadian-American-Ticlopidine Study in thromboembolic stroke. Lancet 1989;1:1215-20.
14. Hass WK, Easton JD, Adams HP, Vernille H, Kunnelis JA, Morrit JH, et al. TASS Ticlopidine Aspirin Stroke Study. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in hig-risk patients. N Engl J Med 1989;321:501-7.
15. Balsamo F, Rizzon P, Violi F, STAI Group Studio della Ticlopidina nell'Angine Instabile. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990;82:17-26.
16. Hebert JM, Savi P. Non-specific inhibition of ADP induced platelet antiaggregation by clopidogrel in vitro [letter]. Throm Haemost 1999;82:156-7.
17. Becker RC, Fintel DJ, Green D. En: Antithrombotic therapy. 4th ed. Baltimore: Balton, 2000; p. 83.
18. Maffrand JP, Bernat A, Delebassee D, Jetile K. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 1998;59:225-30.
19. Defreyn G, Gachet C, Savi P, Laplace MC, Maffrand JP, Bulling A, et al. Ticlopidine and clopidogrel (SR 25990c) selectively neutralize ADP inhibition of PCE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991;65:186-90.
20. Savi P, Laplace MC, Maffrand JP, Bulling A, Gachet C, Roteri F, et al. Binding of [3H]-2-methylthyo ADP to rats platelets-effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994;269:772-7.
21. Savi P, Artcanuthurry V, Bornia J, Laplace MC, Maffrand JP, Bulling A, et al. Effect of clopidogrel treatment on ADP-induced phosphorilations in rat platelets. Br J Haematol 1997;97:185-91.
22. Herbert JM, Savi P, Maffrand JP. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. Eur Heart J Suppls 1999;1(Suppl A):31-40.
23. Gachet C, Stierlé, Cazenave JP. The thienopyridine PCR 4099 selectively inhibits ADO-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990;40:229-38.
24. Gachet C, Savi P, Ohlmann P, Jakobs KH, Cazanave JP, Hu CJ. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes-an effect selectively blocked by thienopyridine clopidogrel. Thromb Haemost 1992;68:79-83.
25. Mills DCB, Puri R, Hu CJ, Mafrand JP, Jakobs KH, Cazenave JP. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteroscl Throm 1992;12:430-6.
26. Savi P, Herbert JM, Pfieger AM. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem pharmacol 1992;44:527-32.
27. Savcic M, Hauert J, Bachmann F. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(Suppl 2):15-9.
28. Cadroy Y, Bossavy JP, Sakariassen KS, Maffrand JP, Jakobs KH, Cazenart JP, et al. Pharmacodynamics of the antithrombotics effects of aspirin and clopidogrel with or without a loading dose versus aspirin alone in an ex vivo model of arterial thrombosis in man [poster]. Actas de American Heart Association Meeting; 1999, noviembre 7-10; Atlanta. Atlanta: American Heart Association Meeting, 1999.
29. Denninger MH, Necciari J, Serre-Lacroix E, Valentine Y, Oslan RE, Kunnirg Z, et al. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost 1999;25(Suppl 2):41-5.
30. Caplain H, Donat F, Gaud C. Parmacokinetics of clopidogrel. Semin Thromb Hemost 1999;25(Suppl 2):29-33.
31. D'Honneur G, Caplain H, Cario R, Necciari J, Herbert JM, Gaud C, et al. Interaction study between clopidogrel and prolonged intravenous heparin administration in young healthy volunteers. Haemostasis 1996;26(Suppl 3): abstract 555.
32. CAPRIE Steering committee. A randomised blinded, trial of clopidogrel versus aspirin in patientes at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
33. Coccheri S, on behalf of the CAPRIE investigators. Distribution of symptomatic atherothrombosis and influence of atherosclerotic disease burden on risk of secondary ischemic events: results from CAPRIE [poster]. Actas de XX Congress of European Society of Cardiology; 1998, agosto 22-26; Vienna. Vienna: European Society of Cardiology, 1998.
34. Rupprecht HJ, on behalf of the CAPRIE investigators. Consistency of the benefit of clopidogrel across a range of vascular-related endpoints: results from CAPRIE [poster]. Eur Heart J 1999;20(Suppl):666.
35. The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Lancet 2001;345: 494-502.
36. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Phramacol Rev 1978;30:293-331.
37. Hirs J. Antiplatelet agents: their mode of action rationale and clinical effectiveness. Prog Pharmacol 1982;4:21-50.
38. Información de medicamentos. Tomo II. USP DI. Madrid: Ministerio de Sanidad y Consumo, 1998.
39. De Gaetano G. Prevención primaria de las enfermedades vasculares con AAS. Lancet (ed. esp.) 1988;1:1093-4.
40. Peto R, Gray R, Collins R, Wernell H, Feteri RL, Goneray I, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
41. Hansson L, Zanchetta A, Carruthers SG, Kuerrt W, Koller JH, Beneriont Z, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351:1755-62.
42. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [published correction appears in BMJ 1994;308:1540]. BMJ 1994; 308:81-6.
43. Borzak S, Cannon CP, Kraft PL. For the TIMI 7 investigators. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. Am J Cardiol 1998;81:678-81.
44. ISIS-2 Ensayo aleatorio con estreptocinasa iv, AAS oral, ambos o ninguno en 17.187 pacientes con sospecha de IM agudo (segundo estudio internacional sobre supervivencia tras IM). Lancet (ed. esp.) 1988;2:349-60.
45. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296: 320-31.
46. Elwood PC, Cocharane AL, Burr ML, Kinery JH, Burnelli C, Moret K, et al. A randomized controlled trial of AAS in the secondary prevention of mortality from myocardial infarction. Br Med J 1974;1:436-40.
47. Mustard JF. Aspirin in the secondary prevention from myocardial infarction. Am J Med 1983;74:43.
48. FDA. AAS e infarto de miocardio. Drug Bull 1985;15:34.
49. UK-TIA Sondey Group United Kingdom tratient ischaemic attack (UK-TIA). Aspirin trial; interin results. BMJ 1988;296:316-20.
50. Coronary Drug Project Group. Aspirin in coronary heart disease. J Chronic Dis 1976;29: 625-42.
51. Estudio AFASAK. Lancet 1989;1:175-9.
52. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964;1:1209-12.
53. Fleming HA, Bailey SM. Mitral valve disease. Systemic embolism and anticoagulants. Postgrad Med J 1971;47:599-604.
54. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
55. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-9.
56. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebovascular ischaemic events. Lancet 1991;338: 1345-9.
57. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high riks patients. BMJ 2002;324:71-86.
58. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
59. The Anturane Reinfarction Trial. Reevaluation of outcome. N Engl J Med 1982;306: 1005-8.
60. Steele PP. Platelet suppressive therapy patients with prosthetic cardiac valves. Circulation 1979;60:910-3.
61. Goldman S, Copeland J, Moritz T. Improvement in early saphenous vein graft patency after coronary artery by-pass surgery with antiplatelet therapy. Circulation 1988; 77:1324-32.
62. Mitchell JRA. Secondary prevention of myocardial infarction, the present state of the art. Br Med J 1980;280:1128-32.
63. Bernal S, Fuster V. Papel del tratamiento inhibidor plaquetario en el IM. Cardiovasc Drugs Ther 1991;1:139-56.
64. Anturane Reinfarction Trial Study (ARIS). Report from the Anturane Reinfarction Italian Study sulfinpyrazone in post myocardial infarction. Lancet 1982;1:237-42.
65. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in treatment stroke. N Engl J Med 1978;299:53-9.
66. Candelise L, Landi G, Perrone P, Tarkel L, Ternerisse HJ, Urkel JJ, et al. Randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 1982;13:175-9.
67. Fornaro G, Rossi P, Mantica P. Indobufen in the prevention of thrombo-embolic complications in patients with heart disease. Circulation 1993;87:162-4.
68. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: the Flurbiprofen French Trial. Eur Heart J 1993;14:951-7.
69. Sánchez de Miguel L, Montón M, Mar Arriero M, Guerra JI, Jiménez A, González-Fernández F, et al. The effect of triflusal on human platelet aggregation and secretion: the role of nitric oxide. Rev Esp Cardiol 2000; 53:205-11.
70. Cruz-Fernández JM, López-Bescós L, García-Dorado D, López García-Aranda V, Cabades A, Martín-Jadraque L, et al. Randomized comparative trial of triflusal and aspirin following myocardial infarction. Eur Heart J 2000;21:457-65.
71. The SYMPHONY investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a ramdomised trial. Lancet 2000;355:337-45.
72. Heeschen C, Hamm CW. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet 2000;355:330-1.
73. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet 1999;353:227-31.